Free Trial

Athersys (ATHX) Stock Price, News & Analysis

0.00 (0.00%)
(As of 07/19/2024 ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
1.77 million shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
ATHX stock logo

About Athersys Stock (NASDAQ:ATHX)

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

ATHX Stock Price History

ATHX Stock News Headlines

Athersys, Inc. (ATHXQ)
Feel the May Shockwave!
Now that the Fed has spoken, it’s sure to create a May Shockwave! Now's your best chance to trade this historic event using the method that has seen Doubles, Even Triples within just a few days! You see, while most folks will be paying $500… $1,000… or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options in a volatile market. You see, by entering on certain predetermined dates, we have been able to watch as these $0.25 Cent Trades doubled, even tripled in what feels like no time.
Toughbuilt Industries Inc (TBLT)
Athersys Inc ATHXQ
Athersys to Sell Most Assets to Healios
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Athersys shares delisted by Nasdaq Stock Market
Athersys crashes after bankruptcy warning
Athersys Director Jane Wasman Appointed Board Chair
See More Headlines
Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($1.33) per share


Free Float
Market Cap
No Data

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Key Executives

  • Mr. Daniel A. Camardo M.B.A. (Age 54)
    CEO, Secretary & Director
    Comp: $796.81k
  • Ms. Z. Kasey Rosado (Age 49)
    Interim Chief Financial Officer
    Comp: $1.51M
  • Ms. Maia A. Hansen M.B.A. (Age 54)
    M.S., Chief Operating Officer
    Comp: $962.57k
  • Senthil Ranganathan Ph.D.
    Vice President of Technical Operations
  • Mr. David Russ M.B.A.
    Vice President of Supply Chain, Finance & Administration
  • Dr. Manal Morsy M.B.A.
    M.D., PH.D., Executive VP & Head of Global Regulatory Affairs
  • Dr. Robert Mays Ph.D.
    Executive VP, Head of Regenerative Medicine & Neuroscience Programs
  • Mr. Rakesh Ramachandran MS
    Head of Information Technology & Communications and VP
  • Dr. Sarah Busch Ph.D.
    VP of Regenerative Medicine & Head of Business Development
  • Ms. Ellen Gurley
    Manager of Corporate Communications and Investor Relations

ATHX Stock Analysis - Frequently Asked Questions

How have ATHX shares performed this year?

Athersys' stock was trading at $0.02 on January 1st, 2024. Since then, ATHX stock has decreased by 88.5% and is now trading at $0.0023.
View the best growth stocks for 2024 here

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($2.00) by $0.25. The biopharmaceutical company had revenue of $4.79 million for the quarter.

When did Athersys' stock split?

Athersys's stock reverse split on Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is William (B.J.) Lehmann's approval rating as Athersys' CEO?

1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

How do I buy shares of Athersys?

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Athersys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT) and Dynavax Technologies (DVAX).

This page (NASDAQ:ATHX) was last updated on 7/20/2024 by Staff

From Our Partners